Linear IgA bullous dermatosis successfully treated with omalizumab: A case report

Maalouf, Nadine S.; Hanna, Dominique

doi:10.1016/j.jdcr.2019.08.019

Cited by 13 publications

(17 citation statements)

References 10 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its usefulness as a novel off‐label treatment alternative for BP has been previously reported in multiple cases, while one case reports its efficacy in the treatment of LABD. 3 , 4 , 10 Although specific IgE directed against the autoantigen BP180 has been shown in BP, the exact mechanism of OMZ in BP, LABD, and LAGBD is not fully understood. 11 Our case report supports the limited amount of evidence of OMZ and its usefulness in the treatment of LABD and LABGD.…”

Section: Discussionmentioning

confidence: 99%

“…OMZ binds free circulating IgE and thereby prevents it from inducing allergic reactions. Its usefulness as a novel off‐label treatment alternative for BP has been previously reported in multiple cases, while one case reports its efficacy in the treatment of LABD 3,4,10 . Although specific IgE directed against the autoantigen BP180 has been shown in BP, the exact mechanism of OMZ in BP, LABD, and LAGBD is not fully understood 11 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report

Haulrig

Nielsen

Elberling

et al. 2022

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report

Haulrig

Nielsen

Elberling

et al. 2022

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…Its usefulness as a novel off-label treatment alternative for BP has previously been reported in multiple cases, while one case reports its efficacy in the treatment of LABD. 3,4,9 Although specific IgE directed against the autoantigen BP180 has been shown in BP, the exact mechanism of OMZ in BP, LABD and LAGBD is not fully understood. 10 Our case report supports the limited amount of evidence of OMZ and its usefulness in the treatment of LABD and LABGD.…”

Section: Discussionmentioning

confidence: 99%

Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A Case report

Haulrig

Nielsen

Elberling

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Monitoring for dapsone adverse reactions can be cumbersome as well. Numerous other treatments have been reported to be effective in the treatment of LAD, including topical corticosteroids, tetracyclines, dicloxacillin, oxacillin, erythromycin, sulfonamides, nicotinamide, rituximab, omalizumab, methotrexate, cyclosporine, etanercept, and intravenous immunoglobulin (IVIg) [1,[5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21]. This review provides updates on the diagnosis of LAD and emerging treatment modalities in order to assess their utility in the management of this disease.…”

Section: Introductionmentioning

confidence: 99%

Updates in the Diagnosis and Management of Linear IgA Disease: A Systematic Review

2021

View full text Add to dashboard Cite

Background and Objectives: Linear IgA disease (LAD) is a rare autoimmune blistering disease with linear IgA deposits along the basement membrane zone. Direct immunofluorescence remains the gold standard for diagnosis, but other diagnostic measures reported in recent literature have proven useful in the setting of inconclusive preliminary results. Dapsone is a commonly used treatment, but many therapeutic agents have emerged in recent years. The objective of this study is to provide a comprehensive overview of updates on the diagnosis and management of LAD. Materials and Methods: A literature search was conducted from May to June of 2021 for articles published in the last 5 years that were related to the diagnosis and management of LAD. Results: False-negative results in cases of drug-induced LAD and the presence of IgG and IgM antibodies on immunofluorescence studies were reported. Serration pattern analysis has been reported to be useful in distinguishing LAD from sublamina densa-type LAD. Rituximab, omalizumab, etanercept, IVIg, sulfonamides, topical corticosteroids, and others have been used successfully in adult and pediatric patients with varying disease severity. Topical corticosteroids were preferred for pediatric patients while rituximab and IVIg were used in adults with recalcitrant LAD. Sulfonamides were utilized in places without access to dapsone. Conclusion: In cases where preliminary biopsy results are negative and clinical suspicion is high, repeat biopsy and additional diagnostic studies should be used. Patient factors such as age, medical comorbidities, and disease severity play a role in therapeutic selection.

show abstract

Linear IgA bullous dermatosis successfully treated with omalizumab: A case report

Cited by 13 publications

References 10 publications

Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report

Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report

Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A Case report

Updates in the Diagnosis and Management of Linear IgA Disease: A Systematic Review

Contact Info

Product

Resources

About